Nilemdo (Bempedoic Acid)

Bempedoic acid, the active ingredient in Nilemdo, is an ATP‑citrate lyase inhibitor presented as an oral tablet for oral use. It lowers low‑density lipoprotein cholesterol and is indicated for primary hypercholesterolemia, heterozygous familial hypercholesterolemia, and patients who cannot tolerate statins in adult patients.

GNH USA supplies Nilemdo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. GNH USA also offers regulatory support and batch traceability to meet local market requirements.

Nilemdo (bempedoic acid) is used to manage disorders of lipid metabolism, particularly elevated LDL‑cholesterol. - Primary hypercholesterolemia: reduces LDL‑cholesterol levels when added to diet and other lipid‑lowering therapies. - Heterozygous familial hypercholesterolemia: provides additional LDL‑cholesterol reduction in patients with genetically elevated cholesterol. - Statin‑intolerant patients: offers an oral lipid‑lowering option for individuals who cannot tolerate statins.

Bempedoic acid may be associated with several adverse reactions, which are categorized by frequency.

Common Side Effects: - Upper respiratory tract infection: mild symptoms such as cough or sore throat. - Musculoskeletal pain: aches or discomfort in muscles or joints. - Elevated liver enzymes: increase in ALT or AST observed in laboratory tests. - Hyperuricemia: rise in serum uric acid levels that may lead to gout flares. - Diarrhea: loose stools occurring intermittently. - Back pain: discomfort in the lumbar region.

Serious or Rare Side Effects: - Tendon rupture: rare but severe tendon injury requiring medical attention. - Severe hypersensitivity: including angioedema, anaphylaxis, or skin reactions. - Rhabdomyolysis: extremely rare muscle breakdown with potential kidney injury.

When prescribing Nilemdo, clinicians should consider several precautionary measures to ensure safe use. - Liver function monitoring: assess ALT and AST levels before initiation and periodically during therapy. - Renal function assessment: evaluate kidney function, especially in patients with pre‑existing impairment. - Hyperuricemia risk: monitor serum uric acid and manage gout symptoms if they arise. - Drug interactions: review concomitant medications that affect cholesterol metabolism or liver enzymes. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks, as safety data are limited. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and light.

Bempedoic acid can interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Statins (especially high‑dose simvastatin): increased risk of myopathy and elevated liver enzymes. - Cytochrome P450 2B6 inhibitors: may raise bempedoic acid plasma concentrations.

Moderate Interactions (Monitor Closely): - Bile acid sequestrants: may reduce absorption of bempedoic acid; separate dosing times. - Fibrates: combined use may enhance liver enzyme elevations. - Anticoagulants (e.g., warfarin): monitor INR as lipid‑lowering therapy can affect coagulation parameters.